Brought to you by 
Eisai to market Arena's lorcaserin in the US; Eisai now has global rights
17 Jul 2018
Executive Summary
Arena Pharmaceuticals Inc. (developing therapeutics that target G protein-coupled receptors) has licensed Eisai Inc. (the US subsidiary of Japanese pharmaco Eisai Co. Ltd.) exclusive US marketing rights to its lorcaserin, which is currently pending FDA approval for obesity and weight management.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai to market Arena's lorcaserin in the US; Eisai now has global rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice